Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | CA5A | P35218 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | TTR | P02766 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2976618 | 0.93 | GAA (0.60) | GAAALDH1A1TDP1TSHRNFKB1 | |
| SCHEMBL2976612 | 0.93 | GAA (0.60) | GAAALDH1A1TDP1TSHRNFKB1 | |
| SCHEMBL5496444 | 0.87 | GAA (0.54) | GAAALDH1A1TDP1TSHRNFKB1 | |
| SCHEMBL5496450 | 0.87 | GAA (0.54) | GAAALDH1A1TDP1TSHRNFKB1 | |
| SCHEMBL2234880 | 0.84 | ALDH1A1 (0.56) | GAAALDH1A1TDP1TSHRSMN1; SMN2 | |
| SCHEMBL375443 | 0.84 | ALDH1A1 (0.56) | GAAALDH1A1TDP1TSHRSMN1; SMN2 | |
| SCHEMBL6293793 | 0.82 | ALDH1A1 (0.62) | GAAALDH1A1SMN1; SMN2LMNAHTT | |
| SCHEMBL2593397 | 0.82 | ALDH1A1 (0.60) | GAAALDH1A1TDP1TSHRNFKB1 | |
| SCHEMBL5673785 | 0.82 | ALDH1A1 (0.60) | GAAALDH1A1TDP1TSHRNFKB1 | |
| SCHEMBL2742576 | 0.81 | ALDH1A1 (0.62) | GAAALDH1A1SMN1; SMN2LMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1802586-A2 | HETEROARYL-SUBSTITUTED ALKYNE COMPOUNDS AND METHOD OF USE | Amgen Inc. (US) | 2007-07-04 | — | — | EP | disclosed |
| US-20070054916-A1 | Aryl nitrogen-containing bicyclic compounds and methods of use | AMGEN INC. | 2007-03-08 | — | — | US | disclosed |
| WO-2006044823-A2 | HETEROARYL-SUBSTITUTED ALKYNE COMPOUNDS AND METHOD OF USE | AMGEN INC. (US) | 2006-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054916-A1 | Aryl nitrogen-containing bicyclic compounds and methods of use | MAP3K1, MAP3K5, MAP3K2 | GAA 3670/4885ALDH1A1 1563/4885TDP1 1980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.